menu
    • menu

    Company profile for AnHorn Medicines

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AnHorn Medicines is a drug discovery company developing therapies that target and degrade disease-related proteins. Our proprietary BIGPRO® technology, built on Targeted Protein Degradation (TPD), aims to treat life-threatening and life-impairing diseases. Focusing on cancer, neurodegeneration, and aging-related conditions, we leverage our AI-enabled AIMCADD® platform to identify high-potential drug candidates. AnHorn is com...
    AnHorn Medicines is a drug discovery company developing therapies that target and degrade disease-related proteins. Our proprietary BIGPRO® technology, built on Targeted Protein Degradation (TPD), aims to treat life-threatening and life-impairing diseases. Focusing on cancer, neurodegeneration, and aging-related conditions, we leverage our AI-enabled AIMCADD® platform to identify high-potential drug candidates. AnHorn is committed to transforming innovation into new therapeutics for challenging and drug-resistant diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AnHorn MedicinesTaiwan Flag
    Country
    Country
    Taiwan
    Address
    Address
    C522, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 115
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.anhornmed.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/anhorn-medicines/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AI-Designed AH-001 Completes US Phase I Trial With Strong Result
    AI-Designed AH-001 Completes US Phase I Trial With Strong Result

    29 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ai-designed-drug-ah-001-complete-us-phase-i-trial-demonstrating-excellent-safety-and-tolerability-302598644.html

    PR NEWSWIRE
    29 Oct 2025
    Share Share
    AnHorn Medicines: First Subject Dosed in AH-001 Phase I US Trial
    AnHorn Medicines: First Subject Dosed in AH-001 Phase I US Trial

    26 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/anhorn-medicines-announces-first-subject-dosed-in-ah-001-phase-i-clinical-trial-in-the-united-states-302410351.html

    PR NEWSWIRE
    26 Mar 2025
    Share Share
    AnHorn Medicines Presents Research of Novel Protein Degrader for Topical Use
    AnHorn Medicines Presents Research of Novel Protein Degrader for Topical Use

    15 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/anhorn-medicines-presents-research-of-novel-protein-degrader-for-topical-use-at-isid-meeting-2023-301819158.html

    PR NEWSWIRE
    15 May 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search